Holen Sie sich die Stockscreener-App
2.51
1.57%
-0.04
Handel nachbörslich:
2.49
-0.02
-0.80%
Schlusskurs vom Vortag:
$2.55
Offen:
$2.51
24-Stunden-Volumen:
764.53K
Relative Volume:
0.49
Marktkapitalisierung:
$275.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-134.24M
KGV:
-1.4181
EPS:
-1.77
Netto-Cashflow:
$-121.34M
1W Leistung:
+8.19%
1M Leistung:
+5.02%
6M Leistung:
-39.23%
1J Leistung:
-59.35%
1-Tages-Spanne:
$2.455
$2.575
1-Wochen-Bereich:
$2.3077
$2.6784
52-Wochen-Spanne:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Firmenname
Annexon Inc
Sektor
Branche
Telefon
(650)-822-5500
Adresse
1400 SIERRA POINT PARKWAY, BRISBANE
Vergleichen Sie ANNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.51 | 279.77M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-05-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | BTIG Research | Buy |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Annexon Inc Aktie (ANNX) Neueste Nachrichten
Is Annexon Inc. a growth stock or a value stockNavigate market shifts with confidence - jammulinksnews.com
What markets is CYCC expanding into Is Annexon Inc. stock a good long term investment optionHigh-profit stock alerts - jammulinksnews.com
What are the technical indicators suggesting about Annexon Inc.Achieve rapid wealth accumulation with smart picks - jammulinksnews.com
Is Annexon Inc. a Top Dividend Stock to Watch in 2025Top Momentum Stock Pick - Newser
How Interest Rate Changes Impact Annexon Inc. Stock PerformanceDouble Profit With Half Risk - Newser
What makes Annexon Inc. stock attractive to long term investorsFree Access to Investment Community - Newser
Annexon Inc. Stock Analysis and ForecastOutperformance with explosive growth - PrintWeekIndia
Why Annexon Inc. stock attracts strong analyst attentionProven Trading Plan - Newser
How Annexon Inc. stock performs during market volatilityFree Predictions - Newser
Annexon Announces Completion of Enrollment in Pivotal Phase - GlobeNewswire
Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy - Ophthalmology Times
Annexon completes enrollment in Phase 3 ARCHER II trial - TipRanks
Annexon Announces Completion of Enrollment in Pivotal Phase 3 AR - GuruFocus
Annexon (ANNX) Completes Enrollment for Phase 3 Trial of Vonapru - GuruFocus
Annexon completes enrollment for phase 3 dry AMD therapy trial - Investing.com Australia
Annexon completes enrollment for phase 3 dry AMD therapy trial By Investing.com - Investing.com South Africa
Annexon, Inc. Completes Enrollment of Phase 3 ARCHER II Trial for Vonaprument, Targeting Vision Preservation in Dry AMD with Geographic Atrophy - Quiver Quantitative
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - Yahoo Finance
What analysts say about Annexon Inc. stockBreakout portfolio performance - Autocar Professional
Is Annexon Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
What drives Annexon Inc. stock priceRapidly expanding wealth - jammulinksnews.com
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - 富途牛牛
Is Annexon Inc. stock a growth or value playHigh Reward Risk Balanced Trading - Newser
Annexon Inc (ANNX) Stock: A Comprehensive 52-Week Review - investchronicle.com
Annexon EVP Yednock sells $2.9k in shares By Investing.com - Investing.com South Africa
Annexon EVP Yednock sells $2.9k in shares - Investing.com India
What makes Annexon Inc. stock price move sharplyTop Performing Stocks - Newser
Finanzdaten der Annexon Inc-Aktie (ANNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):